{'fraction_non_alphanumeric': 0.03110047846889952, 'fraction_numerical': 0.023923444976076555, 'mean_word_length': 4.9361702127659575, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.

PURPOSE
To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.


MATERIALS AND METHODS
This clinical trial was performed on 16 patients with hormone-resistant prostate cancer.


RESULTS
Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events.


CONCLUSION
Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.